Trial Profile
Evaluation of therapeutic efficacy of pH-dependent release formulation of mesalazine in patients with active ulcerative colitis who are resistant to time-dependent release formulation: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2015
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 26 Oct 2015 New trial record